ClinicalTrials.gg
Active, not recruitingNCT07351864FIN-SGLT2-HFUpdated Oct 9, 2026

Finerenone Plus SGLT2 Inhibitors in Heart Failure

A Phase 4 interventional study of Finerenone and dapagliflozine in Heart Failure, sponsored by Mansoura University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Mansoura University · Phase 4, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Planned enrollment
18th of 23
60 · median 120
Started
2026
with 9 others
Phase 4
6 of 23
5 open now
Primary completion
2026-10
later than 2 of 16 live
Registered
16th of 23
by date
Lead sponsor
1 of 23
Mansoura University

Among the 23 studies testing finerenone in Heart Failure, this one is the 18th largest by planned enrollment, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 2 of the 16 other live ones, and was the 16th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.

The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone.

Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.

Read the detailed description

Heart failure is a chronic clinical syndrome associated with significant morbidity, mortality and healthcare burden worldwide, despite advances in pharmacological therapy. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become an important component of standard treatment for patients with heart failure due to their demonstrated cardiovascular benefits. However, a substantial residual cardiovascular risk persists, indicating the need for additional therapeutic strategies.

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with a distinct mechanism of action that targets mineralocorticoid receptor activation in cardiac and renal tissues. Previous clinical studies have demonstrated that finerenone reduces inflammation and fibrosis and provides cardiovascular benefits in patients with chronic cardiovascular and renal diseases. These findings support the potential for finerenone to offer complementary cardioprotective effects when combined with established heart failure therapies.

This prospective controlled pilot study is designed to evaluate the clinical effects and safety of adding finerenone to standard therapy with an SGLT2 inhibitor in patients with heart failure, compared with treatment using an SGLT2 inhibitor alone. Patients receiving stable SGLT2 inhibitor therapy will be managed according to the assigned treatment strategy and followed throughout the study period to evaluate overall clinical outcomes and safety parameters.

The findings of this pilot study are expected to provide preliminary evidence regarding the potential benefits and tolerability of combining finerenone with SGLT2 inhibitors in patients with heart failure and to inform the design of future larger-scale clinical studies.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Finerenone
  • SGLT2 inhibitor
  • Dapagliflozin
  • Heart failure therapy
  • Cardioprotection
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18 - 65 years.
  • Newly diagnosed with HFrEF or HFpEF.
  • Clinically stable and eligible to start SGLT2 inhibitors ± Finerenone therapy.

Exclusion criteria

Exclusion Criteria:

  • Patients with stroke.
  • \<25 mL/min.
  • HF secondary to congenital heart disease or pulmonary hypertension
  • Use intravenous inotropes.
  • Patients needing cardiac transplantation.
  • Known allergy to study medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Finerenone Plus SGLT-2 inhibitor (dapagliflozin)

    Participants in this arm will receive finerenone in addition to standard therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor (dapagliflozin). Finerenone will be administered at a dose of 10 mg once daily and dapagliflozin will be administered at a dose of 10 mg once daily, according to standard clinical practice

    Drug: Finerenone · Drug: dapagliflozine

  • Active comparator
    SGLT-2 inhibitor (dapagliflozin) alone

    Participants in this arm will receive standard therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor (dapagliflozin) alone. Dapagliflozin will be administered at a dose of 10 mg once daily according to standard clinical practice.

    Drug: dapagliflozine

Interventions

  • Finerenone administered orally at a dose of 10 mg once daily.

  • Drugdapagliflozine

    Dapagliflozin administered orally at a dose of 10 mg once daily.

06

What researchers measure

Primary outcomes

  1. Cardiovascular Mortality and Heart Failure Hospitalization

    Incidence of cardiovascular mortality and hospitalization due to heart failure in each treatment group.

    Time frame: Up to 12 weeks (assessed at Baseline, Week 4, and Week 12)

Secondary outcomes

  1. All-cause Mortality

    Number of participants with all-cause mortality in each treatment group.

    Time frame: Up to 12 weeks (assessed at Baseline, Week 4, and Week 12)

  2. Change in NYHA Functional Class

    Change in New York Heart Association (NYHA) functional class in each treatment group.

    Time frame: Up to 12 weeks (assessed at Baseline, Week 4, and Week 12)

  3. Change in Serum Potassium Level

    Serum potassium concentration (mmol/L) measured at baseline, Week 4 and Week 12 in each treatment group.

    Time frame: Up to 12 weeks (assessed at Baseline, Week 4, and Week 12)

  4. Change in Estimated Glomerular Filtration Rate (eGFR)

    Estimated glomerular filtration rate (eGFR, mL/min/1.73 m²) measured at baseline, Week 4 and Week 12 in each treatment group.

    Time frame: Up to 12 weeks (assessed at Baseline, Week 4, and Week 12)

  5. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score

    Change in health-related quality of life assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score in each treatment group. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline and Week 12

07

Study locations

1 site
08

References and documents

Publications

  • Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13. PubMed 34775784 ↗
  • Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E, Milaras N, Samaras A, Theofilis P, Fragakis N, Tousoulis D, Xanthos T, Giannakoulas G. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Curr Probl Cardiol. 2024 Jul;49(7):102615. doi: 10.1016/j.cpcardiol.2024.102615. Epub 2024 Apr 29. PubMed 38692445 ↗
  • Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. PubMed 33264825 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the study team as the study is conducted for academic research purposes and data confidentiality will be maintained.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 9 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2026 → Oct 2026 and completion Jul 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Jan 20, 2026
StartActual
Jan 18, 2026
Primary completionEst.
Oct 31, 2026was Apr 2026
CompletionEst.
Oct 31, 2026was Jul 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 9, 2026
Primary completion
Apr 30, 2026→Oct 31, 2026
Oct 9, 2026
Study completion
Jul 31, 2026→Oct 31, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Active, not recruiting
    Primary completion Apr 30, 2026→Oct 31, 2026
    Study completion Jul 31, 2026→Oct 31, 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351864
Responsible party
Mansour Saad (PhD Candidate in Clinical Pharmacy, Mansoura University) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 18, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Mansour Saad Alqahtani, PhD Candidate
principal investigator · Faculty of pharmacy, Mansoura university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion